达雷妥尤单抗单药治疗中危或高危冒烟型多发性骨髓瘤:CENTAURUS随机开放标签多中心2期研究
CENTAURUS研究纳入123例中危或高危冒烟型多发性骨髓瘤患者,随机分配至达雷妥尤单抗16 mg/kg静脉给药的长程强化、长程中间或短程方案。预设主要分析时完全缓解率未达CR率>15%的共同主要终点,但所有组中位无进展生存期均≥24个月,未观察到新的安全性信号。
要点
- 达雷妥尤单抗单药在中危/高危冒烟型骨髓瘤中未达到CR率>15%的主要终点。
- 所有给药组中位无进展生存期均≥24个月,延长随访后强化组24个月PFS率89.9%。
- 强化给药方案在多数患者中维持目标饱和谷浓度,未观察到新的安全性信号。
核心结论
- 达雷妥尤单抗单药治疗中危或高危冒烟型多发性骨髓瘤未达到CR率>15%的共同主要终点,但各给药组中位无进展生存期均≥24个月。
- 延长随访后强化组和中间组完全缓解率分别为4.9%和9.8%,短程组为0%。
- 药代动力学分析显示强化给药在每周、每2周和每4周给药期间维持目标饱和谷浓度,未观察到新的安全性信号。
研究设计与样本
- 随机、开放标签、多中心2期研究(CENTAURUS),纳入123例中危或高危冒烟型多发性骨髓瘤患者。
- 患者随机分配至达雷妥尤单抗16 mg/kg静脉给药的长程强化、长程中间或短程方案。
主要发现
- 预设主要分析(中位随访15.8个月)时,强化、中间和短程组的完全缓解率分别为2.4%、4.9%和0%。
- 预设主要分析时,强化、中间和短程组的疾病进展/死亡率分别为0.055(80%CI 0.014-0.096)、0.102(80%CI 0.044-0.160)和0.206(80%CI 0.118-0.295),均对应中位无进展生存期≥24个月(P分别<0.0001、<0.0001和=0.0213)。
- 延长随访(中位随访25.9个月)时,强化、中间和短程组的完全缓解率分别为4.9%、9.8%和0%。
- 延长随访时,强化、中间和短程组的疾病进展/死亡率分别为0.059(80%CI 0.025-0.092)、0.107(80%CI 0.058-0.155)和0.150(80%CI 0.089-0.211),均对应中位无进展生存期≥24个月(所有组P<0.0001)。
- 24个月无进展生存率在强化、中间和短程组分别为89.9%(90%CI 78.5-95.4%)、82.0%(90%CI 69.0-89.9%)和75.3%(90%CI 61.1-85.0%)。
关键数值与推荐
- 共同主要终点之一为完全缓解率>15%,本研究未达到该阈值。
- 共同主要终点之二为疾病进展/死亡率,强化组0.055(80%CI 0.014-0.096)、中间组0.102(80%CI 0.044-0.160)、短程组0.206(80%CI 0.118-0.295)。
临床怎么用
- 现行指南推荐冒烟型多发性骨髓瘤在出现多发性骨髓瘤症状前进行积极监测,或入组临床试验。
- 本研究数据为正在进行的达雷妥尤单抗治疗冒烟型多发性骨髓瘤的3期研究提供了依据。
局限性
- 预设主要分析时完全缓解率未达到CR率>15%的共同主要终点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current guidelines for smoldering multiple myeloma (SMM) recommend active monitoring until the onset of multiple myeloma (MM) before initiating treatment or enrollment in a clinical trial. Earlier intervention may delay progression to MM. In CENTAURUS, 123 patients with intermediate-risk or high-risk SMM were randomly assigned to daratumumab 16 mg/kg intravenously on extended intense (intense), extended intermediate (intermediate), or short dosing schedules. At the prespecified primary analysis (15.8-month median follow-up), the complete response (CR) rates (co-primary endpoint) were 2.4%, 4.9%, and 0% for intense, intermediate, and short dosing, respectively; the co-primary endpoint of CR rate >15% was not met. Progressive disease (PD)/death rates (number of patients who progressed or died divided by total duration of progression-free survival [PFS] in patient-years; co-primary endpoint) for intense, intermediate, and short dosing were 0.055 (80% confidence interval [CI], 0.014-0.096), 0.102 (80% CI, 0.044-0.160), and 0.206 (80% CI, 0.118-0.295), respectively, translating to a median PFS ≥24 months in all arms (P < 0.0001, <0.0001, and =0.0213, respectively). With longer follow-up (median follow-up, 25.9 months), CR rates were 4.9%, 9.8%, and 0% for intense, intermediate, and short dosing, respectively. PD/death rates for intense, intermediate, and short dosing were 0.059 (80% CI, 0.025-0.092), 0.107 (80% CI, 0.058-0.155), and 0.150 (80% CI, 0.089-0.211), respectively, again translating to a median PFS ≥ 24 months in all arms (P < 0.0001 for all arms). Twenty-four-month PFS rates were 89.9% (90% CI, 78.5-95.4%), 82.0% (90% CI, 69.0-89.9%), and 75.3% (90% CI, 61.1-85.0%) for intense, intermediate, and short dosing, respectively. Pharmacokinetic analyses indicated that intense dosing maintained target-saturating trough concentrations in most patients throughout weekly, every-2-week, and every-4-week dosing periods. No new safety signals were observed. These data provide the basis for an ongoing phase 3 study of daratumumab in SMM.
引用
- Landgren CO, Chari A, Cohen YC, et al. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia. 2020. PMID: 32024950. doi:10.1038/s41375-020-0718-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。